drugset

Drugs / BBT002

Follow last change Jun 2026 re-read 3 minutes ago

BBT002

Developed for: chronic obstructive pulmonary disease · chronic rhinosinusitis
Investigated by: Bambusa Therapeutics

Trials 3

today NCT07436949 · Ph 1/2 NCT07288554 · Ph 1 NCT06944925 · Ph 1

20262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT07288554	Sep 2025 → Dec 2026 expected	chronic obstructive pulmonary disease	Bambusa Therapeutics	Recruiting	No outcome recorded
Phase 1	NCT06944925	May 2025 → Jan 2027 expected	chronic obstructive pulmonary disease	Bambusa Therapeutics	Recruiting	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT07436949	Mar → Dec 2026 expected	chronic rhinosinusitis	Bambusa Therapeutics	Not yet recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 2

Date	Issuer	Release
2026-06-15	Bambusa Therapeutics	Results Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 bambusatx.com ↗
2026-05-18	Bambusa Therapeutics	Results Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial bambusatx.com ↗

All press releases naming this drug 5 releases

Date	Issuer	Release
2026-06-15	Bambusa Therapeutics	Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 bambusatx.com ↗
2026-05-18	Bambusa Therapeutics	Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial bambusatx.com ↗
2026-01-21	Bambusa Therapeutics	Bambusa Therapeutics Abstract on BBT002 Accepted for Oral Presentation at ATS 2026 bambusatx.com ↗
2026-01-06	Bambusa Therapeutics	Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum bambusatx.com ↗
2025-05-30	Bambusa Therapeutics	Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001 bambusatx.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	BBT002	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288554 ↗ 2 NCT06944925 ↗ NCT07436949 ↗
Route	Intravenous	“BBT002 will be given by intravenous injection or subcutaneous injection.” NCT06944925 ↗
Route	Subcutaneous	“BBT002 will be given by intravenous injection or subcutaneous injection.” NCT06944925 ↗